Northwire Canada EditionThursday, July 16, 2026
Sign inSubscribe
Northwire
⌕
CLCH 1.17 −4.1% DG 0.035 +0.0% SGML 15.86 −6.0% FURY 0.730 −2.7% CG 22.11 −1.9% ARIS 20.18 −1.1% LAF 1.65 +0.0% MKO 10.18 −2.2% NUG 0.330 −1.5% SGN 0.250 −5.7% AVL 7.99 −0.4% ELE 22.14 −2.7% TRX 1.03 −7.2% PTM 1.83 +0.6% OMM 0.050 −9.1% CBG 0.300 −1.6% CLCH 1.17 −4.1% DG 0.035 +0.0% SGML 15.86 −6.0% FURY 0.730 −2.7% CG 22.11 −1.9% ARIS 20.18 −1.1% LAF 1.65 +0.0% MKO 10.18 −2.2% NUG 0.330 −1.5% SGN 0.250 −5.7% AVL 7.99 −0.4% ELE 22.14 −2.7% TRX 1.03 −7.2% PTM 1.83 +0.6% OMM 0.050 −9.1% CBG 0.300 −1.6%
Financings

Hemostemix closes $480,000 financing

By The Northwire Desk — AI Analysis Dec 31, 2025 · 18:13 HEM · 0.09 Hemostemix Inc
HEM · Price

Executive Summary

  • Hemostemix Inc. has closed a non-brokered private placement raising aggregate gross proceeds of $480,000.
  • The company issued 4,000,000 common shares at a price of $0.12 per share.
  • Proceeds are designated for general working capital, specifically to advance regulatory, clinical, and commercialization initiatives for its autologous angiogenic cell therapy platform, ACP-01 (VesCell).

Key Details

  • Transaction Type: Non-brokered private placement.
  • Gross Proceeds: $480,000.
  • Share Price: $0.12 per common share.
  • Shares Issued: 4,000,000 common shares.
  • Use of Proceeds: General working capital, including advancing regulatory, clinical, and commercialization initiatives for ACP-01 (VesCell).
  • Regulatory Status: Subject to final acceptance by the TSX Venture Exchange (TSX-V).
  • Restrictions: All securities are subject to a statutory hold period in accordance with applicable securities laws and TSX-V policies.

Notable Quotes

  • No direct quotes from management were included in the provided text.
Read the original news release →

More from Hemostemix Inc

Jun 26, 2026 · 08:48

Pre-revenue stem cell therapy developer advancing ACP-01 across ischemic indications while navigating severe liquidity constraints and ongoing dilutive financings.

Financings Jun 17, 2026 · 17:23

Micro-cap Biotech Cuts Financing Price in Half Amid Restatement and Going Concern Warnings

Financings Feb 03, 2026 · 08:56

Hemostemix Appoints Renowned Vascular Surgeon and Principal Investigator, Dr. York Hsiang, as Business Consultant to Advance First Nations-Led Healthcare Partnerships

Management Jan 16, 2026 · 16:06

Hemostemix gets FDA support for basket protocol

Regulatory Jan 16, 2026 · 12:27

Hemostemix Receives FDA Support for Its Basket Protocol Approach

Regulatory Dec 31, 2025 · 14:39

Hemostemix Closes $480,000 Private Placement at $0.12 per Share

Financings